amr industry alliance

uniting to act on antimicrobial resistance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

read more

We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:

Invest in R&D to meet public health needs with new innovative diagnostics & treatments
Improve access to high-quality antibiotics and ensuring that new ones are available to all
Work to reduce the development of antimicrobial resistance
Support measures to reduce environmental impact from production of antibiotics

shared goals

We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.

progress report

In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.

in action

Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.

latest news

12/11/2018

The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders

The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all st...

Read more
08/06/2018

Multiple Alliance Members Co-sign the Canadian Declaration on Antimicrobial Resistance

The International Council of Biotechnology Associations (ICBA) supports the Canadian Declaration on Combatting Antimicrobial Resistance, signed by biopharmaceutical and diagnostic companies in Canada...

Read more
18/01/2018

Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come

The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The re...

Read more

amr in numbers

AMR Impact

Life-sciences at the forefront of the battle against AMR

Development of National Action Plans

R&D

Biotechs

Diagnostics

from the blog

Posted on 15/11/2018
By Thomas Cueni, Director General, IFPMA, Chair, AMR Industry Alliance

By 2050, superbugs may cost the economy $100 trillion

This oped was first published in the Antimicrobial Resistance campaign in the Guardian on 12 November 2018. ANTIBIOTIC RESISTANCE Evidence suggests superbugs could cost the global economy up to 3.5% of GDP – and push 28 million more people into poverty. Drastic solutions and innovation is need...

Read more view all

stay informed

Subscribe to receive our updates

  • I consent to the storage of my data according to the Privacy Policy